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Retinoids, vitamin A analogues that bind to retinoic acid receptor (RAR) or retinoid X receptor (RXR), play important roles in
regulating cell proliferation, apoptosis, and differentiation. Recently, RXR-selective ligands, also referred to as rexinoids, have been
investigated as potential chemopreventive agents for breast cancer. Our previous studies demonstrated that the rexinoid bexarotene
significantly prevented ER-negative mammary tumourigenesis with less toxicity than naturally occurring retinoids in animal models. To
determine whether bexarotene prevents cancer at the early stages during the multistage process of mammary carcinogenesis, we
treated MMTV-erbB2 mice with bexarotene for 2 or 4 months. The development of preinvasive mammary lesions such as
hyperplasias and carcinoma-in-situ was significantly inhibited. This inhibition was associated with reduced proliferation, but no
induction of apoptosis. We also examined the regulation of a number of rexinoid-modulated genes including critical growth and cell
cycle regulating genes using breast cell lines and mammary gland samples from mice treated with rexinoids. We showed that two of
these genes (DHRS3 and DEC2) were modulated by bexarotene both in vitro and in vivo. Identification of these rexinoid-modulated
genes will help us understand the mechanism by which rexinoid prevents cancer. Such rexinoid-regulated genes also represent
potential biomarkers to assess the response of rexinoid treatment in clinical trials.
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Despite earlier diagnosis and treatment advances, breast cancer
remains the leading health threat to women (Jemal et al, 2005).
Moreover, the annual incidence rate of breast cancer in the United
States has increased steadily over the last two decades, only falling
in the last few years (Edwards et al, 2002). This high incidence rate
has prompted strong interest in breast cancer prevention. The past
chemoprevention studies have focused heavily on antioestrogen
drugs, which include selective oestrogen receptor modulators
(tamoxifen and raloxifene) and aromatase inhibitors. These agents
are effective in reducing the risk of ER-positive breast cancer.
However, they all act against oestrogen signalling pathways and are
unable to prevent ER-negative breast cancer, which accounts for
one-third of all breast cancers and has a particularly poor
prognosis (Cuzick et al, 2003). Recently, a number of novel
chemopreventive agents targeting oestrogen-independent signal-
ling pathways have been developed. Among them, retinoids have
been shown to prevent the development of ER-negative mammary
tumours in animal models (Wu et al, 2000, 2002a,b). In addition,
clinical data show that synthetic retinoid fenretinide significantly
reduced the occurrences of both contralateral and ipsilateral breast
cancer incidence in premenopausal women (Veronesi et al, 1999,
2006). More importantly, fenretinide was observed to reduce
secondary tumours irrespective of the hormone receptor status of
the primary cancer (Menard et al, 2001), suggesting that retinoids
have potential chemopreventive effect towards ER-negative breast
cancer.
Retinoids are vitamin A analogues that bind nuclear retinoid
receptors, retinoic acid receptor (RAR) and/or retinoid X receptor
(RXR). The ligand-bound receptors form dimeric complexes that
interact with DNA at specific retinoid-responsive elements and
regulate the transcription of target genes that control cellular
proliferation, differentiation, and apoptosis (Yang et al, 1999).
Based on this nuclear receptor specificity, retinoids can be
categorised as RAR-selective, RXR-selective, or as pan-agonists,
which bind both RAR and RXR. Previous studies demonstrated
that 9cRA, a naturally occurring retinoid that binds both RAR and
RXR, is effective in preventing ER-negative mammary tumorigen-
esis in C3(1)-SV40 T-antigen transgenic mice; however this
pan-agonist had significant toxicity (Wu et al, 2000). TTNPB, an
RAR-selective retinoid, was highly toxic and was not able to
prevent breast cancer in mouse models (Wu et al, 2002a). In
contrast, the RXR-selective retinoid bexarotene (LGD1069,
Targretin) was effective in preventing ER-negative mammary
tumorigenesis in mice, and had less toxicity than 9cRA and the
RAR-selective retinoids (Wu et al, 2002a). Thus, RXR-selective
retinoids (also referred to rexinoids) represent more effective and
more tolerable agents for the prevention of breast cancer.
Subsequently, we reported that bexarotene significantly delayed
ER-negative mammary tumour formation in MMTV-erbB2 and
Revised 25 February 2008; accepted 27 February 2008; published online
25 March 2008
*Correspondence: Dr PH Brown;
E-mail: pbrown@breastcenter.tmc.edu
British Journal of Cancer (2008) 98, 1380–1388
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
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negative mammary tumours, suggesting that the well-tolerated
rexinoid is an effective agent for the prevention of ER-negative
breast cancer.
Although significant progress has been made towards under-
standing the RAR/RXR mediated signalling pathway, the mechanism
by which bexarotene suppresses tumourigenesis is still poorly
understood. Mammary carcinogenesis in humans is a chronic and
multistage process that proceeds through normal epithelium,
atypical hyperplasia, ductal carcinoma in situ (DCIS), and invasive
breast cancer (Beckmann et al, 1997). Similarly, tumours devel-
oped in MMTV-erbB2 transgenic mice also arise through a
multistage process (Kosanke et al, 2004). Bexarotene inhibits cell
proliferation in normal human mammary epithelial cells (Wu et al,
2006), suggesting that it will prevent tumour formation at the early
stages during the chronic multistage carcinogenesis. In this
study, we investigated the ability of bexarotene to prevent the
development of premalignant lesions in MMTV-erbB2 mice. The
results demonstrated that bexarotene significantly prevented the
development of premalignant mammary lesions (hyperplasias,
DCIS-like lesions, and microscopic invasive breast cancers).
Biomarker studies also identified a number of bexarotene-
modulated genes both in vivo and in vitro. Many of these genes
play an important role in cell growth regulation. These biomarkers
will be further tested in future clinical trials, and will help us to
understand the mechanisms by which rexinoids prevent breast
cancer.
MATERIALS AND METHODS
Transgenic mice, cell lines, and retinoids
All animal studies were performed in an ethical manner and were
conducted only after review and approved by the Institutional
Animal Care and Use Committee at Baylor College of Medicine.
The procedures are in compliance with the United Kingdom
Coordinating Committee on Cancer Research guidelines. Female
MMTV-erbB2 transgenic mice were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA). Mice were housed in the
institutional animal facilities and fed a controlled diet of MIN-76A
Purified Diet (Harlan Teklad, Madison, WI, USA). Before the
treatment, the females received under the right kidney capsule, a
pituitary isograft to chronically stimulate the mouse mammary
tumour virus (MMTV) promoter (as described by Lydon et al
(1999)). Virgin animals were used to avoid confounding effects of
hormonal surges during pregnancy. Normal human mammary
epithelial cells (HMEC) were obtained from Clonetics (San Diego,
CA, USA). HMECs were maintained in Mammary Epithelial Basal
Medium supplemented with the Mammary Epithelial Growth
Media kit (Cambrex Corporation, East Rutherford, NJ, USA).
Media were changed every 2 days. Retinoids and rexinoids were
obtained from Ligand Pharmaceuticals Inc. (San Diego, CA, USA).
Treatment and data collection
For short-term treatment, mice were randomised into four
experimental groups with 19 mice in each group. The mice were
treated with sesame oil or bexarotene (100mgkg
 1) for 6 days per
week. We previously demonstrated that 100mgkg
 1day
 1 of
bexarotene used in these mice can achieve peak plasma levels
that are similar to those from human trials using 200–
400mgm
 2day
 1 (Rizvi et al, 1999; Wu et al, 2002a). The mice
were allowed to age to 3 months before treatment to avoid affecting
normal mammary gland development during puberty. Bexarotene
was suspended in purified sesame oil (Croda Inc., Mill Hall, PA,
USA) and administered by oral gavage using a 20-gauge gavage
needle in a volume of 0.1ml. The mice were killed at the age of 5
months (2 month treatment) or 7 months (4 month treatment). For
2 month treatment, both no. 4 mammary glands were resected,
fixed in 4% neutral buffered formalin (4% formaldehyde,
phosphate-buffered) overnight and then embedded in paraffin.
For the mice treated for 4 months, one no. 4 mammary gland was
embedded in paraffin, and the other no. 4 mammary gland was
prepared for whole mount analyses. After 4 months of treatment,
the no. 4 inguinal mammary glands were harvested, spread onto
slides, and fixed with 4% formaldehyde overnight. The glands were
placed in 70% ethanol for 1h and in water for 30min. The slides
were then stained with 0.2% carmine overnight. The mammary
glands were dehydrated sequentially in 70, 90, and 100% ethanol
for 30min each, and cleared in toluene to dissolve fat in the gland.
The slides were maintained in methyl salicylate for analysis under
light microscope.
For biomarker analyses, MMTV-erbB2 mice were randomised
into two groups with 20 mice in each group. Mice were treated with
vehicle or bexarotene (100mgkg
 1) for 6 days per week from 3
months to 5 months of age. At the time of killing, both no. 4
mammary glands were harvested and mammary epithelial pellets
were prepared as described (Medina and Kittrell, 2000). Mammary
epithelial pellets from four mice were pooled into one sample, and
split for RNA and protein isolation.
Histology and immunohistochemical analyses
Paraffin embedded tissues were sectioned at 4mm, and processed
for hematoxylin and eosin staining for routine histological
assessments. Primary antibodies used for immunohistochemical
staining include anti-BrdU (clone Bu20a; Dako, Carpinteria, CA,
USA), and anti-cleaved caspase-3 (1:100, no. 9661, Cell Signaling
Technology Inc., Danvers, MA, USA). Briefly, the slides were
deparaffinised, and then endogenous peroxidase was blocked in
3% hydrogen peroxide buffer. Samples were incubated with
primary antibodies at 41C overnight followed by incubation with
biotinylated rabbit anti-mouse antibody (1:100) for 30min.
Peroxidase activity was visualised using Vector NovaRed substrate
kit (SK-4800, Vector, Burlingame, CA, USA). The slides were
counterstained with hematoxylin for 30s and then mounted with
cover slips.
Quantitative reverse-transcriptase PCR
Total RNAs were isolated using RNeasy Mini Kit (Qiagen,
Valencia, CA, USA). The amount of specific RNA transcripts was
assayed by quantitative reverse-transcriptase PCR (QRT–PCR)
using gene-specific double fluorescence-labeled probes and an ABI
PRISM 7700 Sequence Detector (Applied Biosystems, Foster City,
CA, USA). The PCR reaction mixture consisted of 300nM of each
primer, 100nM of probe, 0.025Uml
 1 of Taq Polymerase, 125mM of
each dNTP, 3mM MgCl2, and 1  Taq Polymerase buffer. Cycling
conditions were 941C for 1min, followed by 40 cycles at 941C for
12s and 601C for 30s. All primers and probes were designed with
Primer Express 1.0 software (Applied Biosystems Foster City, CA,
USA). 6-Carboxy fluorescein was used as the 50 fluorescent
reporter, whereas blackhole quencher was added to the 30 end.
Standard curves for the quantification of each transcript and
cyclophilin were generated using a serially diluted solution of
synthetic templates. Genome equivalent copies were calculated
from the standard curve and normalised by the amount of
cyclophilin. All reactions were performed in triplicate.
Western blotting analysis
Proteins were isolated by using cell lysis buffer (50mM Tris-HCL
pH 8.0, 2% SDS, and protein kinase inhibitor cocktail). Cell lysates
were sheared on ice using a 22G needle and centrifuged at
10000 g for 30min. The protein concentration of the super-
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snatant was measured by BCA protein assay (Smith et al, 1985).
Proteins (30mg) were resolved on a 10% SDS–polyacrylamide gel.
Proteins were then transferred to a nitrocellulose membrane,
which was blocked in 5% nonfat dry milk TBST (10mM Tris pH
8.0, 150mM NaCl and 0.05% Tween 20) at room temperature for
1h. Membranes were probed with the primary antibodies in 1%
nonfat dry milk/TBST. Membranes were then probed with the
corresponding horseradish peroxidase-conjugated secondary
antibodies in TBST. The blots were visualised using the ECL
Western blot detection system (Amersham Life Sciences, Piscataway,
NJ, USA). Involucrin (IVL) and b-actin antibodies were
obtained from Sigma (St Louis, MO, USA). Differentially
Expressed in Chondrocyte 2 (DEC2) antibody was provided by
Dr Bingfang Yan.
Statistical analyses
In the premalignant lesion experiment, numbers of mammary
gland showing preinvasive and invasive lesions were counted
and analysed by Fisher’s exact tests. Immunohistochemical
staining of BrdU and cleaved caspase 3 were compared between
vehicle and LG100268 groups by Wilcoxon rank sum test. RNA
and protein expressions of biomarkers were compared by
student’s t-test (two-tail). Po0.05 was considered as statistically
significant.
RESULTS
Bexarotene prevents the development of premalignant
mammary lesions in MMTV-erbB2 transgenic mice
To determine the effect of rexinoids on the development of
premalignant mammary lesions, we chose an ER-negative mam-
mary tumourigenesis model that simulates oncogenic events seen
in human breast cancer (Hutchinson and Muller, 2000). The
tumours arising in these animals show strong similarity to human
ER-negative, ErbB2-postitive breast cancer as shown in a recent
paper (Herschkowitz et al, 2007). MMTV-erbB2 mice carry the
unactivated, wide-type erbB2 proto-oncogene whose expression is
targeted to breast tissue by the MMTV promoter/enhancer. Similar
to carcinogenesis in humans, mammary tumourigenesis in
MMTV-erbB2 transgenic mice is a multistage process that
proceeds through hyperplasia, mammary intraepithelial neoplasia
(MIN, similar to human DCIS), and invasive cancer (Campiglio
et al, 2004). Pituitary transplants stimulate the transcription of
erbB2 gene through activation of the MMTV promoter, and thus
promote the development of premalignant and malignant mam-
mary lesions. These mice develop focal tumours beginning at 8
months of age. Therefore, the treatment started at 3 months of age
and ended at 5 and 7 months of age (see scheme in Figure 1A), at
which time no mice had palpable mammary tumours developed.
Treat daily by oral gavage 
       End points:
Histology 
(ADH, MIN (DCIS), IBC)
Biomarker expression 
Harvest all mammary glands 
MMTV-wt erbB2 
Vehicle
LGD1069 (100 mg kg–1) 
5 months 3 months 7 months
<0.001 0.170 0.170 0.002 Fisher’s exact test  (P)
3 1 1 1 19 LGD1069
14 4 4 10 19 Vehicle 4 months
0.053 1.00 0.500 0.053 Fisher’s exact test  (P)
0 0 0 0 19 LGD1069
4 0 1 4 19 Vehicle 2 months
Any lesions Invasive
Tumour
MIN Hyperplasia 
Number of mammary gland showing  Number of
glands
examined
Groups Treatment
Normal Hyperplasia MIN IBC 
200 m2 0 0   m2 0 0   m2 0 0   m  
2-month Rx 4-month Rx
A
B
Figure 1 Bexarotene prevents the development of premalignant mammary lesions in MMTV-erbB2 mice. (A) Treatment scheme. Beginning at 3 months
of age, MMTV-erbB2 mice were treated daily for 6 days per week by oral gavage with either vehicle or bexarotene. The mice were killed after 2 or 4 months
of treatment. Mammary tissues were prepared for whole-mount analysis, histology examination, and biomarker measurement. (B) Mammary tissue sections
were stained with hematoxylin and eosin. For each mouse, we examined one slide from the no. 4 mammary gland for histological analysis. Numbers of
mammary gland showing hyperplasias, mammary intraepithelial neoplasias, and invasive mammary tumours were shown. P-values were obtained with Fisher’s
exact tests, generated for each type of lesion individually.
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sNormal appearing mammary glands were then removed and
processed for histological and biomarker analyses. For these
experiments, we examined the frequency of hyperplasias, MIN
lesion, and cryptic invasive cancer in these mice. As shown in
Figure 1B, at age of 5 months, 21% (4 out of 19) of vehicle-treated
mice developed hyperplasias and only one mouse showed a MIN
lesion. No invasive breast cancer was detected. In contrast, no
hyperplasias or MIN lesions were detected in bexarotene-treated
mice. In total there were four animals showing premalignant or
cryptic invasive cancers in vehicle-treated mice as compared to
none in the bexarotene-treated mice. This difference approached
statistical significance (P¼0.053), but did not reach the cutoff for
significance (defined as Po0.05). At 7 months of age, we observed
an increased numbers of premalignant lesions as well as cryptic
microscopic invasive cancers. Compared to vehicle-treated mice,
bexarotene-treated mice developed fewer preinvasive and invasive
mammary cancers. Specifically, the number of hyperplasias was
significantly reduced (Po0.01, two-sided Fisher’s exact test) by
bexarotene treatment. Total number of all lesions was also reduced
significantly (Po0.01). The number of glands showing MIN
lesions or cryptic invasive cancers was also reduced but did not
reach statistical significance (P¼0.17) due to small numbers of
lesions. These results suggest that bexarotene prevents mammary
tumourigenesis through blocking the development of premalig-
nant lesions.
Bexarotene inhibits mammary epithelial proliferation
Previous results have shown that bexarotene significantly inhibits
cell growth in normal mammary epithelial cells (Wu et al, 2006).
Proliferation inhibition and apoptosis promotion are two major
causes of growth suppression. To determine which mechanism
occurs during bexarotene-induced growth suppression, we exami-
ned the effect of bexarotene on proliferation and apoptosis by
measuring the levels of BrdU incorporation and cleaved caspase 3.
Baseline proliferation of mammary epithelium in MMTV-erbB2
mice was around 10%, higher than the proliferation rate of normal
human mammary gland. This is due to the overexpression of
erbB2, which stimulates the epithelial proliferation. Bexarotene
significantly reduced mammary gland proliferation at both 2
month and 4 month treatments (Po0.01, assessed by Wilcoxon
rank sum test; Figure 2A). Proliferation was reduced by 40% (10 to
6%) after two months of treatment and by 35% (from 10 to 6.5%)
after 4 months of treatment. Next, we determined whether
bexarotene induced apoptosis by measuring the proportion of
cells staining positive for cleaved caspase 3. As shown in Figure 2B,
less than 1% of mammary epithelial cells showed positive caspase 3
staining. There is no statistical difference in the proportion of cells
undergoing apoptosis between vehicle and bexarotene-treated
mice, suggesting that induction of apoptosis is not responsible for
the cancer preventive effect of bexarotene.
Bexarotene treatment has no effect on mammary gland
development
To determine whether bexarotene has any effect on mammary
gland development, we examined the mammary gland in whole
mount after 4 months treatments. As shown in Figure 3C,
mammary glands in these mice showed a secretory pattern due
to the stimulation from pituitary isograft. When mammary glands
from vehicle and bexarotene-treated mice were compared, there
was no difference in overall size of the mammary glands or in the
number of terminal branches. This result is in contrast to that seen
with fenretinide in previous study using a rat model (Radcliffe and
Moon, 1983). This may be because we treated mice only after 3
months of age when the mammary glands had fully developed, or it
may be due to the specific animal model used in our study.
Analyses of gene expression in bexarotene-treated breast
cells using RT–PCR
As a nuclear receptor ligand, bexarotene exerts its biological
activity primarily through modulate the expression of its target
genes through RXR. Identification of these genes will help us to
understand how rexinoid inhibits cell proliferation and prevents
mammary carcinogenesis, and will also identify useful biomarkers
for future clinical trials of bexarotene and other rexinoids. We
previously have performed Affymetrix Microarray analysis of
normal human mammary epithelial cells treated with vehicle or
bexarotene (Kim et al, 2006). These studies identified many
rexinoid regulated genes. Table 1 shows a subset of these rexinoid-
regulated genes that were up- or downregulated more than twofold
and that were found to show a significant change after a students
t-test (selected from an initial nonstringent analysis, Po0.05). In
addition, we also examined DEC genes, which are known
retinoid-modulated genes that control cell cycle and proliferation
(Boudjelal et al, 1997; Azmi et al, 2004). We validated the
selected gene with reverse transcriptase-polymerase chain reaction
(RT–PCR) using independent RNA samples from dimethyl
sulphoxide (DMSO) or bexarotene-treated HMEC cells. Among
them, 39% (7 out of 18 genes) show significant modulation
(Po0.05).
Validation of array data
To further confirm these rexinoid modulated genes, we measured
RNA or protein expression levels of selected bexarotene-regulated
genes by real-time quantitative RT–PCR and western blotting.
Among the 7 genes that had a significant fold change, modulation
of ID1, COX-2, and ODC was previously described (Kim et al,
2006). We examined another four genes including DEC2, DHRS3,
IVL, and RAI3. Three independent sets of total RNA and
protein were prepared from DMSO or bexarotene-treated HMEC
cells. As shown in Figure 3A, all four genes are modulated
by bexarotene significantly after 24h treatment. We also measured
the protein expression of DEC2 and IVL in HMEC cells. As shown
in Figure 3B, both genes are induced by bexarotene (Po0.05
t-test).
Bexarotene modulates biomarkers in the mammary glands
of mice
We have demonstrated that bexarotene regulated specific bio-
markers in vitro (as shown in Table 1 and Figure 3). Next, we
investigated whether bexarotene modulates the expression of these
biomarkers in vivo. For these experiments, we isolated RNA and
protein from mammary epithelial pellets prepared from MMTV-
erbB2 mice treated with daily oral gavage of vehicle or bexarotene
for 2 months as described in Materials and Methods. At this age,
no palpable tumours had developed. The mammary epithelial
tissue isolated from the MMTV-erbB2 mice is analogous to breast
tissue sample obtained from high-risk women in the clinical
chemoprevention studies. As shown in Figure 4A, the RNA
expression of four biomarkers (DHRS3, DEC2, IVL, and RAI3)
was all modulated by bexarotene in mammary gland cells
(although the change in IVL and RAI3 expression did not reach
statistical significance). DHRS3 was induced by 300% whereas
DEC2 was induced by 79% (Po0.05). We also demonstrated that
DEC2, a gene that regulates the cell cycle and cellular proliferation,
was significantly induced by bexarotene at the protein level in the
mammary gland epithelial cells (Figure 4B). The consistency of the
in vivo and in vitro data suggests that these rexinoid-regulated
biomarkers will be useful to assess the response to rexinoid
treatment in breast cancer prevention clinical trials.
Bexarotene prevents premalignant mammary lesion
YL iet al
1383
British Journal of Cancer (2008) 98(8), 1380–1388 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sA
B
P=0.0015  P =0.0041 
100 m 100 m
100 m
100 m
100 m 100 m
100 m
BrdU incorporation 
4 months
Vehicle LGD1069
0
1
2
3
4
5
6
7
8
9
10
11
2 months
Vehicle LGD1069
0
1
2
3
4
5
6
7
8
9
10
11
Vehicle LGD1069
0.0
0.1
0.2
0.3
0.4
0.5
%
P=0.71
Positive control: mouse c-myc  
mammary tumour 
P
e
r
c
e
n
t
a
g
e
 
o
f
 
B
r
d
U
 
i
n
c
o
r
p
o
r
a
t
i
o
n
P
e
r
c
e
n
t
a
g
e
 
o
f
 
B
r
d
U
 
i
n
c
o
r
p
o
r
a
t
i
o
n
LGD1069 Vehicle
Vehicle LGD1069 Vehicle LGD1069
C
Positive control: mouse c-myc  
mammary tumour 
Vehicle Bexarotene
Figure 2 Bexarotene inhibits the proliferation of mammary epithelium. (A) Quantitative analysis of BrdU incorporation rate in mammary epithelium from
vehicle and bexarotene-treated mice. Mice were treated with vehicle or bexarotene (100mgkg
 1) for 2 or 4 months and tissue sections were prepared
from paraffin-embedded tissues. Immunohistochemical staining of BrdU was performed as described in ‘Materials and Methods’. Data were generated from
19 animals of each experimental group. Positive stained cells were quantitated from at least 1000 cells. (B) Quantitative analyses of cleaved caspase 3
expression in mammary epithelium from mice treated with vehicle or bexarotene for 4 months. Immunohistochemical staining of cleaved caspase 3 was
performed as described in ‘Materials and Methods’. Data were generated from 10 animals of each experimental group. Positive stained cells were
quantitated from at least 1000 cells. The bars represent s.e. Statistical analyses were assessed with Wilcoxon rank sum test. (C) Comparison of mammary
gland development in vehicle and bexarotene-treated mice. MMTV-erbB2 mice were treated with vehicle or bexarotene (100mgkg
 1) from the age of 3
months to 7 months. Representative whole mount pictures of the no. 4 mammary gland prepared at the end of each treatment are shown.
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Figure 3 Measurement of rexinoid-modulated genes in vitro.( A) Measurement of RNA expression. HMECs were treated with DMSO or bexarotene
(1mM) for 8 or 24h. Total RNAs were isolated. Expression of genes were assessed with quantitative real-time RT–PCR. The expression of each gene was
normalised by the expression level of cyclophilin. (B) Measurement of protein expression. HMECs were treated with DMSO or bexarotene (1mM) for 24h.
Total proteins were isolated. Expression of genes was assessed with western blotting. The expression of each gene was normalised by the expression level of
b actin. The columns represent mean values of three independent experiments. The bars represent s.d. Statistical analyses were assessed with student’s
t-test. DMSO, dimethyl sulphoxide; HMECs, human mammary epithelial cells; RT–PCR, reverse transcriptase-polymerase chain reaction.
Table 1 Selection of bexarotene-modulated genes by RT–PCR
RT–PCR
Gene Full name Array results Fold changes P
ID1 Inhibitor of DNA binding 1 Up 5.7 m5.60 0.036
DHRS3 Dehydrogenase/reductase (SDR family) member 3 Up 2.8 m7.47 0.012
RAI3 Retinoic acid induced 3 Up 3.1 m3.49 0.042
IVL Involucrin Up 2.8 m2.81 0.049
C-fos Homologous to the (FBJ) murine osteosarcoma virus oncogene Up 2.7 m1.79 0.067
DDIT4 DNA damage inducible transcript 4 Up 4.1 m1.27 0.285
DSIPI Delta sleep-inducing peptide, immunoreactor Up 2.4 m0.92 0.877
GDI-2 Rho GDP dissociation inhibitor 2 Up 2.0 m1.20 0.261
DEC1 Differentially expressed in chondrocyte 1 m1.08 0.795
DEC2 Differentially expressed in chondrocyte 2 m2.71 0.023
Cox-2 Prostaglandin–endoperoxide synthase 2 Down 4.9 k3.91 0.045
ASNS Asparagine synthetase Down 4.0 k2.47 0.201
PCK 2 Phosphoenolpyruvate carboxykinase 2 Down 2.0 k2.42 0.053
TLS/CHOP TLS–CHOP hybrid gene Down 4.5 k1.69 0.091
Wnt7a Wingless-type MMTV integration site family, member 7A Down 4.3 k1.72 0.082
ATF3 Activating transcription factor 3 Down 6.3 k1.43 0.083
ODC1 Ornithine decarboxylase 1 Down 2.2 k2.12 0.034
IER2 Immediate early response 2 Down 2.3 k1.07 0.722
Array results represent the ratio of gene expression in bexarotene vs DMSO-treated HMECs determined by an initial nonstringent analysis of Affymetrix microarray (Kim et al,
2006). Fold changes represent the ratio of gene expression in bexarotene vs DMSO-treated HMECs for 24h determined by RT–PCR. Whose results were generated from
three independent experiments. P-values were calculated by using student’s t-test.
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sDISCUSSION
The clinical evidence of fenretinide in preventing secondary breast
cancer irrespective of ER status has provided strong rationale to
investigate the chemopreventive role of retinoids/rexinoids. We
have shown that rexinoid bexarotene is an effective agent to
prevent the development of ER-negative breast cancer in MMTV-
erbB2 mice. However, the mechanism by with bexarotene prevents
tumour development is not fully understood. In this study we
investigated the effect of bexarotene on the development of
preinvasive mammary lesions. Our results demonstrated that
rexinoid bexarotene prevents the development of breast cancer at
the early stages during the multistage process of tumourigenesis by
suppressing the development of hyperplasias, DCIS-like MIN
lesions, and microscopic invasive cancers. Prevention of cancer is
associated with reduced proliferation of mammary epithelial cells
and with changes in several growth regulating genes. Many of these
genes are critical regulators of cell cycle progression and
proliferation, and in combination likely mediate rexinoid-induced
growth suppression.
Our present results showed that bexarotene suppressed deve-
lopment of hyperplasias, suggesting that this rexinoid prevents the
cancer at an early step during tumourigenesis. This is also
supported by our published data showing that the proliferation
inhibition by bexarotene was more profound in normal
mammary epithelial cells than in breast cancer cells (Wu et al,
2006). Previous studies showed that bexarotene inhibited the
breast cancer cell proliferation in vitro (Wu et al, 2002a) and
carcinogen-inducted mammary tumour growth in vivo (Bischoff
et al, 1999). The antiproliferation effect on both normal and
malignant mammary epithelial cells suggests that bexarotene can
prevent both the initiation and progression of mammary
carcinogenesis. The significant inhibition of mammary epithelial
hyperplasias also suggests that the major effect of bexarotene takes
places at the early stages during the multistage process of
tumourigenesis.
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Figure 4 Measurement of rexinoid-modulated genes in vivo. MMTV-erbB2 mice were treated with daily oral gavage of vehicle or bexarotene
(100mgkg
 1) for 2 months starting from 3 months of age. Mammary epithelial pellets were prepared for RNA and protein isolation. Each sample was
pooled from four mice. (A) Measurement of RNA expression. Expressions of genes were assessed with quantitative real-time RT–PCR. The expression of
each gene was normalised by the expression level of cyclophilin. (B) Measurement of protein expression. Expressions of genes were assessed with western
blotting. The expression of each gene was normalised by the expression level of b actin. The columns represent mean values of four pooled samples, as one
sample in each group had substantially low yield of RNA/protein and was excluded. The bars represent s.d. Statistical analyses were assessed with student’s
t-test. RT–PCR, reverse transcriptase-polymerase chain reaction.
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proliferation inhibition, as determined by BrdU incorporation rate
(Figure 2A). The proportion of cells that undergo apoptosis was
not increased after 4 months treatment of bexarotene (Figure 2B).
This is consistent with our previous results, in which rexinoid did
not promote apoptosis in normal mammary epithelial cells (Wu
et al, 2006). Christov et al (2007) found that short-term treatment
with high dose of bexarotene (150mgkg
 1) induced apoptosis in
methylnitrosourea-induced mammary cancers in rat (Christov
et al, 2007). However, in MMTV-erbB2 mice, we did not observe
apoptosis induction in mammary epithelium at the dose of
100mgkg
 1. Sporn’s group also found that the rexinoid
LG100268 did not induce apoptosis in vivo and in vitro, although
it did synergise with arzoxifene to promote apoptosis (Suh et al,
2002; Rendi et al, 2004). Recent data showed that both rexinoids
(bexarotene and LG100268) significantly downregulate cyclin D1
expression and block cell cycle progression in normal and
malignant breast cells (Wu et al, 2006). In addition, Yu et al
(2006) and Landis et al (2006) demonstrated that mice lacking
cyclin D1 activity were protected from developing erbB2-induced
mammary tumours. In this study, we observed a 35–40% of
proliferation inhibition by bexarotene. This antiproliferative effect
is much more profound than that of gefitinib, which only reduced
the mammary epithelial proliferation by 20% (Lu et al, 2003).
Other investigators have published results showing that bexarotene
inhibits proliferation in methylnitrosourea-induced mammary
cancers in rats by approximately 75% (Lubet et al, 2005; Christov
et al, 2007). However, the 75% reduction was observed in
methylnitrosourea-induced rat tumours, while the 35–40% reduc-
tion was observed in normal mammary glands in MMTV-erbB2
mice. We have recently completed a phase II clinical trial using
bexarotene to prevent breast cancer in high-risk women at Baylor
College of Medicine. The clinical results showed that daily
administration of bexarotene (200mgm
 2) for 28 days signifi-
cantly decreased the expression level of cyclin D1 in normal
mammary epithelium from post-menopausal women. Bexarotene
also decreased the expression of Ki67 by approximately 50%
although the result failed to reach statistical significance due to the
small sample size (Brown et al, 2007). The clinical data support our
hypothesis that bexarotene prevents cancer through growth
inhibition of mammary gland. These data also suggest that
blocking cell cycle progression thorough downregulating cyclin
D1 plays critical role in rexinoid-induced proliferation inhibition.
We found that several rexinoid-modulated genes were modu-
lated in the mammary glands from bexarotene-treated mice. These
include a metabolism enzyme (DHRS3), differentiation marker
(IVL), and genes involved in growth regulation (DEC2, RAI3, ID1,
and COX2). Our results show that these rexinoid-modulated genes
can be used as biomarkers to demonstrate a biological effect on the
target tissue (the mammary gland).
Among the bexarotene modulated genes, DEC2 (Differentially
expressed in chondrocytes 1) is particular interesting. Bexarotene
induced DEC2 both in vivo and in vitro. DEC2 is a member of DEC
protein subfamily, which consists of DEC1 and DEC2. Both DEC
proteins belong to the basic helix-loop-helix transcription factor.
DEC1 was originally identified as a retinoid induced gene
(Boudjelal et al, 1997; Shen et al, 1997), whereas DEC2 was first
identified through EST analysis (Fujimoto et al, 2001). We
examined the regulation of DEC proteins and found that DEC2,
but not DEC1, was induced by bexarotene. Previous studies
showed that DEC proteins are potent transcription repressors by
binding to DNA at E-box (St-Pierre et al, 2002; Li et al, 2003).
Azmi et al (2003) also found that forced expression of DEC2
inhibited cell proliferation and down-regulated cyclin D1 expres-
sion in C2C12 myoblasts. Thus, induction of DEC2 by bexarotene
suggests that DEC2 may mediate rexinoid-induced growth
suppression.
Our previous studies demonstrated that cyclin D1 was repressed
by rexinoids bexarotene and LG100268 (Kim et al, 2006; Wu et al,
2006; Li et al, 2007). Thus, the expression of cyclin D1 is
inversely related to DEC2 expression. This inverse correlation
raises the possibility that DEC2 might repress cyclin D1.
Consistent with this hypothesis, our QPCR data showed
that DEC2 was induced by bexarotene at as early as 8h of
treatment. In contrast, downregulation of cyclin D1 by bexarotene
was a late effect and was not observed at 8h of treatment (data not
shown), supporting the proposal that DEC2 may play role in
suppressing cyclin D1 expression. In addition, another rexinoid
downregulated gene, ODC, is known to be regulated by c-myc
via an E-box regulatory element. It is possible that DEC2 affects
ODC expression in a manner similar to its downregulation of
cyclin D1.
These data indicate that rexinoid bexarotene prevents the
development of ER-negative mammary tumour at the early stages
during the multistage carcinogenesis process in MMTV-erbB2
transgenic mice. The cancer preventive effect is primarily due to
inhibition of the proliferation of normal and premalignant breast
epithelial cells. We have also shown that rexinoid-regulated genes
can be potentially used as biomarkers to show the effects of
rexinoids on mammary tissue. These biomarkers will be useful in
monitoring the effects of rexinoids in cancer preventive clinical
trials. Identification of rexinoid-modulated growth control genes
has also helped us in understanding the mechanism by which
bexarotene prevents breast cancer.
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